Evidence map›Paper›PMID 28627326›Full record

ArticleMolecular imaging2017

Triphenylamines Induce Cell Death Upon 2-Photon Excitation.

Rahima Chennoufi, Florence Mahuteau-Betzer, Patrick Tauc, Marie-Paule Teulade-Fichou, Eric Deprez

Open access · goldAbstract read
In one paragraph

Article in Molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Rahima Chennoufi1 LBPA, CNRS UMR8113, IDA FR3242, ENS Cachan, Université Paris-Saclay, Cachan, France.
Florence Mahuteau-Betzer2 Chemistry, Modeling and Imaging for Biology, UMR9187-U1196, Institut Curie, Centre universitaire, Orsay, France.
Patrick Tauc1 LBPA, CNRS UMR8113, IDA FR3242, ENS Cachan, Université Paris-Saclay, Cachan, France.
Marie-Paule Teulade-Fichou2 Chemistry, Modeling and Imaging for Biology, UMR9187-U1196, Institut Curie, Centre universitaire, Orsay, France.
Eric Deprez1 LBPA, CNRS UMR8113, IDA FR3242, ENS Cachan, Université Paris-Saclay, Cachan, France.
École Normale Supérieure Paris-Saclay · FRInstitut Curie · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photodynamic therapy (PDT) is a promising therapeutic method for several diseases, in particular for cancer. This approach uses a photosensitizer, oxygen, and an external light source to produce reactive oxygen species (ROS) at lethal doses to induce cell death. One drawback of current PDT is the use of visible light which has poor penetration in tissues. Such a limitation could be overcome by the use of novel organic compounds compatible with photoactivation under near-infrared light excitation. Triphenylamines (TPAs) are highly fluorescent compounds that are efficient to induce cell death upon visible light excitation (458 nm), but outside the biological spectral window. Interestingly, we recently showed that TPAs target cytoplasmic organelles of living cells, mainly mitochondria, and induce a high ROS production upon 2-photon excitation (in the 760-860 nm range), leading to a fast apoptosis process. However, we observed significant differences among the tested TPA compounds in terms of cell distribution and time courses of cell death-related events (apoptosis vs necrosis). In summary, TPAs represent serious candidates as photosensitizers that are compatible with 2-photon excitation to simultaneously trigger and imaging cell death although the relationship between their subcellular localization and the cell death mechanism involved is still a matter of debate.

Indexed as

ApoptosisCell DeathHumansOptical ImagingPhotochemotherapyPhotosensitizing AgentsReactive Oxygen SpeciesPhotosensitizing AgentsReactive Oxygen Speciesactivatable probesadvances in optical probescell deathfluorescence imagingimaging cellular stressphotodynamic therapy

Identifiers

PMID28627326
PMCPMC5480627
OpenAlexW2671127762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.